高效调节剂治疗时代预测接受鼻窦手术的因素
这项前瞻性观察性多中心研究纳入60例成人囊性纤维化合并慢性鼻窦炎患者,其中24例(40%)选择内镜鼻窦手术。多变量回归显示,SNOT-22总分更差与选择手术相关(OR 1.09,95%CI 1.02-1.16,p=0.015),而接受elexacaftor/tezacaftor/ivacaftor(ETI)治疗与继续药物治疗相关(OR 0.04,95%CI 0.004-0.34,p=0.004)。
要点
- SNOT-22总分更差与选择内镜鼻窦手术相关(OR 1.09,95%CI 1.02-1.16)。
- 接受ETI治疗与继续药物治疗相关(OR 0.04,95%CI 0.004-0.34)。
- 肺病严重程度和鼻窦CT评分与选择手术无关。
核心结论
- 更差的鼻窦症状负担、缺乏ETI治疗、睡眠质量、抑郁和鼻内镜评分与选择内镜鼻窦手术相关,而肺病严重程度和鼻窦CT评分则无关。
- ETI使用与追求内镜鼻窦手术的较低 odds 相关,且独立于鼻窦症状负担。
研究设计与样本
- 前瞻性、观察性、多机构研究,纳入成人囊性纤维化合并慢性鼻窦炎患者60例,其中24例(40%)选择内镜鼻窦手术。
主要发现
- 选择内镜鼻窦手术与更差的SNOT-22总分、鼻科、心理和睡眠功能障碍域评分相关(所有p<0.050)。
- 选择内镜鼻窦手术与更差的PHQ-9-R抑郁评分、更差的PSQI总分相关(所有p<0.050)。
- 选择内镜鼻窦手术与更差的CFQ-R体重、角色、情绪和进食域评分相关(所有p<0.050)。
- 选择内镜鼻窦手术与鼻内镜下更严重的疾病及缺乏调节剂治疗相关(所有p<0.050)。
- 多变量回归显示,更差的SNOT-22总分与选择内镜鼻窦手术相关(OR 1.09,95%CI 1.02-1.16,p=0.015),ETI治疗与继续药物治疗相关(OR 0.04,95%CI 0.004-0.34,p=0.004)。
关键数值与推荐
- SNOT-22总分更差与选择内镜鼻窦手术的OR为1.09(95%CI 1.02-1.16,p=0.015)。
- ETI治疗与继续药物治疗的OR为0.04(95%CI 0.004-0.34,p=0.004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comorbid chronic rhinosinusitis (CRS) remains unresolved for many people with cystic fibrosis (PwCF). While highly effective modulator therapy improves quality-of-life and symptom severity, the impact of this intervention and other factors associated with pursuing endoscopic sinus surgery (ESS) remains understudied. METHODS: Adult PwCF + CRS were enrolled into a prospective, observational, multi-institutional study. Participants completed validated outcome measures to evaluate respiratory symptom severity, depression, headache, and sleep quality, as well as nasal endoscopy, sinus computed tomography (CT), and olfactory testing. Bivariate comparisons and regression modeling evaluated treatment cofactors, disease characteristics, and outcome measures associated with pursuing ESS. RESULTS: Sixty PwCF were analyzed, including 24 (40%) who elected ESS. Pursuing ESS was associated with worse SinoNasal Outcome Test (SNOT-22) total, rhinologic, psychological, and sleep dysfunction domain scores; worse Patient Health Questionnaire-9-Revised depression scores; worse Pittsburgh Sleep Quality Index total scores; worse weight, role, emotion, and eating domain scores on the Cystic Fibrosis Questionnaire-Revised; more severe disease on nasal endoscopy; and lack of modulator therapy (all p < 0.050). Multivariable regression identified that worse SNOT-22 total score was associated with electing ESS (odds ratio [OR] 1.09, 95% confidence interval [CI] 1.02-1.16, p = 0.015) and elexacaftor/tezacaftor/ivacaftor (ETI) treatment (OR 0.04, 95% CI 0.004-0.34, p = 0.004) was associated with pursing medical therapy. CONCLUSIONS: Worse sinonasal symptom burden, lack of ETI treatment, sleep quality, depression, and nasal endoscopy scores were associated with electing ESS, while lung disease severity and sinus CT scores were not. ETI use was associated with lower odds of pursuing ESS independent of sinonasal symptom burden.
引用
- Beswick DM, Han EJ, Mace JC, et al. Factors that predict pursuing sinus surgery in the era of highly effective modulator therapy. Int Forum Allergy Rhinol. 2023. PMID: 37725072. doi:10.1002/alr.23270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。